Corcept Therapeutics | CORT - Sales Revenues


Corcept Therapeutics reported $256.15M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 307.96M 39.9M Jun/2026
Alaunos Therapeutics USD 2K 2K Mar/2025
ANI Pharmaceuticals USD 266M 28.5M Jun/2026
Ardelyx USD 94.47M 30.74M Mar/2026
Aurora Cannabis CAD 38.01M 56.18M Mar/2026
BioMarin Pharmaceutical USD 990M 224M Jun/2026
Bristol-Myers Squibb USD 12.97B 1.48B Jun/2026
Canopy Growth CAD 71.25M 3.29M Mar/2026
Corcept Therapeutics USD 256.15M 91.25M Jun/2026
Eli Lilly USD 22.97B 3.17B Jun/2026
J&J USD 25.31B 1.21B Jun/2026
Knight Therapeutics CAD 133.11M 11.56M Dec/2025
Lexicon Pharmaceuticals USD 5.49M 8.69M Dec/2025
Merck USD 16.6B 310M Jun/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Novartis USD 14.41B 1.3B Jun/2026
Novartis USD 13.11B 750M Mar/2026
Pacira USD 192.4M 15.4M Jun/2026
Pfizer USD 15.03B 530M Jun/2026
Supernus Pharmaceuticals USD 219.1M 11.39M Jun/2026
TG Therapeutics USD 240.34M 45.54M Jun/2026